Charles S. Fuchs named SVP at Roche and Genentech

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

The incidence of multiple cancer types in people under the age of 50 has been rising, with early-onset cancers now contributing to nearly 15,000 excess cases of cancer in the U.S. annually.

March 27, 2026

By W. Kimryn Rathmell

Trials & Tribulations

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

March 27, 2026

By Richard M. Goldberg

Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

NCI

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.

March 20, 2026

Vol.52 No.11

By Claire Marie Porter

NCI

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

The National Cancer Advisory Board has established an ad hoc working group that will assess cancer centers as part of the designation process. The decision was approved unanimously with one abstention at the NCAB meeting March 17.

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

NCI Director Anthony Letai appeared before the National Cancer Advisory Board Committee March 17 to maneuver through thorny topics while reiterating his message of reassurance: Stability. Stability. Stability.

March 20, 2026

Vol.52 No.11

By Jacquelyn Cobb

Charles S. Fuchs named SVP at Roche and Genentech

YOU MAY BE INTERESTED IN

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Renew today!

Subscriber content

Never miss an issue!

Login

Charles S. Fuchs named SVP at Roche and Genentech

YOU MAY BE INTERESTED IN

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?”

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Never miss an issue!

Login

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”